Navigation Links
Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Date:1/10/2008

substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: risks relating to the Company's ability to maintain its Nasdaq listing (including the risk that the Company may not successfully appeal a Nasdaq delisting determination); Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating and debt service requirements; the success of Amarin's research and development activities, including its planned clinical trials in cardiovascular disease and; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; general changes in International and US generally accepted accountin
'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
(Date:5/28/2015)... May 28, 2015  PDS Biotechnology Corp. announces ... treatment targeting HPV-16, has generated strong T-cell responses ... pre-cervical cancer is treated by surgical removal of ... effective non-surgical alternative. Results show that it primes ... recognize, target, and kill precancerous and cancerous cells ...
(Date:5/28/2015)... New York and London (PRWEB) May 28, 2015 ... CFD-focused provider of Computer Aided Engineering software, announced ... Solid Research, Inc. (PSRI). CD-adapco will provide state-of-the-art ... PSRI members will share their expertise and experiences ... chemical and refining industry members and advance the ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Auxogyn, Inc., a privately held medical technology company ... acquired an exclusive license from Stanford University to develop ... in the field of assisted reproduction to significantly improve ... procedures. The technology licensed from Stanford is ...
... Calif., Oct. 4 Dainippon Sumitomo Pharma Co., Ltd. ... have entered into an option agreement to co-develop a ... the agreement, DSP has received an option for exclusive ... a promising cell therapy drug candidate being developed by ...
... BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... of OncoGenex will present at the 9th Annual BIO Investor ... The Palace Hotel in San Francisco, CA. Live ... Relations page of the OncoGenex Web site at http://ir.oncogenex.com ...
Cached Biology Technology:Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University 2Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... de dezembro de  2012 A Integrated Biometrics, ... a certificação pelo FBI de sua novíssima tecnologia ... IB criou o novo produto usando a tecnologia ... com um transistor de película fina (TFT). A ...
... methodologies of identifying genes that contribute to the ... in several immune-system-related pathways contribute to development of ... 4 in the open-access journal PLOS ONE ... function in autism by integrating analysis of autism-associated ...
... and Cargill have renewed their partnership to eliminate lymphatic filariasis ... disease that affects over 2 million Haitians and is the ... is truly a national disease in Haiti and 87 percent ... of coastal Haiti, as much as half of the population ...
Cached Biology News:Integrated Biometrics Apresenta Sherlock, o Menor, Mais Leve e Fino Sensor Appendix F Mobile ID 2Combining two genome analysis approaches supports immune system contribution to autism 2Combining two genome analysis approaches supports immune system contribution to autism 3Cargill expands support of Notre Dame Haiti Program 2Cargill expands support of Notre Dame Haiti Program 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Agarose Gel Loading Dye Mixture 6X...
Biology Products: